Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2026 /CourierPR/ -- Wave Life Sciences, a clinical-stage biotechnology company dedicated to RNA medicines, will present at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026. President and CEO Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at 9:45 a.m. Eastern Time.

The presentation will be live-streamed on the company’s website, accessible through the “Investor Events” section at https://ir.wavelifesciences.com/events-publications/events. A replay will be available for a limited time after the event.

Wave Life Sciences, headquartered in Cambridge, Massachusetts, focuses on leveraging RNA medicines to address both rare and common diseases. The company’s PRISM® platform integrates multiple modalities and chemistry innovations, enabling breakthrough treatments. Wave’s portfolio includes candidates for obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease, among others.

Dr. Bolno will discuss the company’s strategy and recent developments during the conference. Wave is committed to advancing scientific understanding and therapeutic innovation to improve human health, driven by its mission to "Reimagine Possible."

Wave Life Sciences has several ongoing clinical programs, including those for Duchenne muscular dystrophy and Huntington’s disease. The company also has a number of preclinical programs leveraging its RNA medicines platform.